Clinical Trial Update: On Open-Label Study in Participants With Systemic Lupus Erythematosus [Phase 3]

View source ↗

Summary

A Phase 3 open-label study in systemic lupus erythematosus was terminated and results were posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Connective Tissue Disease
• Systemic Lupus Erythematosus

Snippet

Sponsor: Eli Lilly and Company | Conditions: Systemic Lupus Erythematosus, Connective Tissue Disease | Phase 3 | Status: TERMINATED | Results posted: 2018-05-17